Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells. JMML incidence approaches 1.2
Introduction
Juvenile myelomonocytic leukemia (JMML) is a lethal myeloproliferative disease (MPD) of young childhood char acterized clinically by overproduction of myelomonocytic cells and by the in vitro phenotype of hematopoi etic progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) [1, 2] . In contrast to nor mal subjects, the morphological composition of progenitor colonies from JMML patients is predominantly macrophages and monocytes [3, 4] . It is notable, however, that progenitor colonies from JMML patients contain monocytic cells along the full spectrum of differentiation, including blast forms, promonocytes, monocytes, and macrophages. This distinct characteristic indicates that JMML is not a disease induced by a complete block in differentiation as observed in acute leukemias, but instead results from shunting of hematopoi etic differentiation toward the monocytic pathway, similar to increased granulocytic differentiation in the chronic phase of chronic myeloid leukemia (Fig. 1) . In addition to mono cytic cell overproduction, patients often present with anemia, thrombocytopenia, and 50% of patients also present with ele vated fetal hemoglobin, hemoglobin F (Hgb F) [5] . JMML patients can progress to blast crisis, usually with French American-British (FAB) M4 or M5 morphology, but more frequently succumb to disease due to tissue infiltration of myeloid cells. Standard cytotoxic chemotherapy in JMML is ineffective, producing few durable remissions [6] . Even following the rigorous therapy of allogeneic hematopoi etic stem cell transplantation (HSCT), the probability of ; No. of Pages 8
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Fig. 1. Schematic diagram of (A) normal hematopoietic differentiation; (B) accumulation of undifferentiated myeloblasts representing acute myeloid leukemia; and (C) increased production of monocytic cells along the full spectrum of differentiation, including blast forms, promonocytes, monocytes, and macrophages, as observed in juvenile myelomonocytic leukemia. HSC = hematopoietic stem cell; CMP = common myeloid progen itor; GMP = granulocyte monocyte progenitor. event-free survival at 5 years is only 50% [7] and the main cause of treatment failure continues to be leukemia relapse.
Activating mutations of the NRAS and KRAS genes and disruption of the tumor suppressor gene NF1 have long been recognized as pathogenic in this disease [8] [9] [10] [11] [12] . More recently, somatic mutations in PTPN11, which encodes the protein tyrosine phosphatase, Shp2, have been found in 35% of JMML cases [13] [14] [15] . Intriguingly, it is now evident that de novo JMML, as well as several of the neuro-cardio-facio-cutaneous congenital disorders in which a JMML-like MPD has been associated [16] [17] [18] [19] , are caused by gene mutations (somatic in the former and germline in the latter) contributing to hyperactivation of the Ras-mitogen activated protein kinase pathway (MAPK, Fig. 2 ) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
Molecular genetics

Learning from patients
The clinical presentation of JMML has provided clini cians and researchers with crucial clues to the molecular aberrancies underlying this rare disease. First, young children with the congenital disorder, neurofibromatosis type 1 (NF1), have an increased incidence of malignant myeloid disorders, including JMML [16, 17] . The characterization of neurofi bromin (encoded by NF1) as a Ras GTPase activating protein (GAP) [32, 33] that normally restricts Ras activation sug gested that dysregulation of Ras activation contributes to the pathological process of JMML. Furthermore, the finding that loss-of-function NF1 mutations are mostly non-overlapping with gain-of-function KRAS and NRAS mutations in JMML patients strongly implicates Ras hyperactivation in JMML [12] . Similarly, the predisposition of some children with Noo nan syndrome (NS), 50% of whom bear germline PTPN11 mutations [20, 34] , to develop a JMML-like MPD [18, 19] prompted investigators to test children with non-syndromic, de novo JMML for somatic PTPN11 mutations [13] [14] [15] . Taken together, 35% of patients have gain-of-function muta tions in PTPN11, 35% gain-of-function mutations in NRAS or KRAS, and another 15% have clinical NF 1. Rarely, patients have been described to harbor dual mutations in these molecules and there is active investigation to determine if these mutations exist in separate hematopoietic progenitor cells.
Correlating genotype with phenotype
For potential improved prognostication of JMML, inves tigators are performing studies to examine if NF1, RAS, and PTPN11 mutational status yields predictive clinical course information for patients. Increased age (>4 years), increased fetal hemoglobin (HgF, >15%), and reduced platelets (<33,000/�L) consistently correlate with a poor out come (reduced event free survival and overall survival) of JMML patients following allogeneic HSCT; however, the potential correlation of gene mutational status with clini cal outcome is unknown. Matsuda and colleagues made the observation that three children with JMML bearing mutations of NRAS or KRAS (2 with NRAS G12S and 1 with KRAS G12S ) demonstrated a mild clinical course with spontaneous remis sion without HSCT [35] . These findings suggested that certain RAS alleles may correlate with favorable clinical out comes. However, in a follow-up study, Flotho and associates were unable to confirm that certain RAS alleles are associ ated with long-term survival in the absence of HSCT [36] . older age at diagnosis (>24 months), increased HgF (>10%), reduced overall survival, and, importantly, appeared to be an unfavorable prognostic factor predicting relapse following transplantation [37] .
Designing accurate murine models
Definition of key mutated genes in JMML has permit ted basic researchers to develop in vivo models of JMML. Hematopoietic progenitors from Nf1 −/− and Kras G12D mice demonstrate elevated Ras-GTP, hypersensitivity to GM-CSF, and produce MPD in vivo [38] [39] [40] . Conditional inactiva tion of Nf1 in hematopoietic cells induces MPD with 100% penetrance, hypersensitivity to GM-CSF, and resistance to apoptosis [41] . Likewise, wild type mice reconstituted with fetal liver progenitors from Nf1 −/− animals develop MPD similar to JMML which is attenuated in mice lacking GM CSF [42] . Currently, Braun, Shannon, and others are utilizing Kras G12D mice and mice bearing a conditional deletion allele of Ptpn11 [43] to examine the question of whether Shp2 functions upstream, downstream, or in parallel to Ras in GM-CSF-stimulated signaling, in normal hematopoiesis, and in the pathogenesis of JMML. Their studies indicate that Shp2 functions at least partly downstream or parallel to Ras in hematopoietic stem cells, similar to that observed in Drosophila [44] , although more recent results indicate that Ras is downstream of Shp2 in myeloid progenitors (B. Braun, personal communication). Furthermore, while Shp2 phosphatase activity is needed for leukemogenesis, it is dis pensible for normal hematopoiesis [45] [46] [47] . An additional in vivo model of JMML was developed by Neel and colleagues using retroviral transduction of murine hematopoietic stem cells with gain-of-function Ptpn11 mutants (Shp2 D61Y and Shp2 E76K ) followed by transplantation into lethally irradi ated recipients [46] . Similar to mice bearing loss-of-function Nf1 or gain-of-function Kras mutations, mice expressing gain-of-function Shp2 also developed MPD in vivo [46] . To remove some of the uncertainty of variable disease onset following adoptive transfer of retrovirally transduced cells, however, Chan and Neel have developed a conditional knockin allele of Shp2 D61Y (LSL-Shp2 D61Y ) [48] . Consistent with results obtained from mice transplanted with mutant Shp2 expressing cells, the LSL-Shp2 D61Y mice develop MPD by 5-7 months following induced expression of Shp2 D61Y . However, unlike the transplanted mice, the LSL-Shp2 D61Y mice also develop anemia, thus recapitulating more closely the phenotype commonly observed in JMML patients [48] . Using these sophisticated genetic in vivo models, researchers continue to seek unique and novel molecules that can be rationally targeted for improved therapeutic tactics in JMML.
Advances in JMML diagnosis and surveillance
Redefining the criteria for diagnosis
In addition to the basic science studies that are being expanded, improved diagnostic, prognostic, and relapse detection techniques are currently under development. The current diagnostic criteria for JMML include absolute mono cyte count > 1000/�L, <20% blasts in the bone marrow, and absence of the BCR-ABL fusion gene plus two of the four following criteria: (1) circulating myeloid precursors; (2) WBC > 10,000/�L; (3) increased fetal hemoglobin (HbF) for age; or (4) hematopoietic progenitor hypersensitivity to GM-CSF (Table 1) . However, based on the identification of LR-3189; No. of Pages 8 Table 2) . While hematopoietic progenitor hypersensitivity to GM CSF has traditionally been used as a minor diagnostic criteria for JMML (Table 1) , it is a time-consuming and cumbersome assay to perform using conventional cell culture methods. To address this problem, Kotecha, Nolan, and Loh have evaluated the correlation between GM-CSF-stimulated acti vation of STAT5, detected using phosphoflow cytometry for phospho-STAT5, with GM-CSF-stimulated hematopoietic progenitor colony growth in JMML patients and healthy con trols [49] . The GM-CSF-stimulated phospho-STAT5 assay yielded results very similar to that of the traditional GM CSF-stimulated hematopoietic progenitor assay, providing a novel diagnostic test that is 95% specific and 91% sensitive and that reduces the diagnosis time from weeks to days. Addi tionally, differences in GM-CSF-stimulated phospho-STAT5 levels might be utilized to identify targeted agents with poten tial efficacy as well as to follow response to treatment, relapse, or transformation to acute myeloid leukemia, which may be particularly relevant in patients receiving experimental or traditional chemotherapeutic agents.
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Redefining the criteria for response
In the past, response to chemotherapy for JMML has been defined using a complicated assessment of white blood cell count, platelet count, and organomegaly (Table 3a) . However, in 2006, the International JMML Working Group meeting in Geneva discussed this topic. First, there was general agree ment on the importance of developing new agents that may be biologically active in the treatment of JMML. The goals Table 2 Proposed JMML diagnostic criteria. Table 3b . Following allogeneic stem cell transplantation, response to therapy and detection of minimal residual disease can be assessed by following donor chimerism; however, no good method exists for tracking molecular responses to ther apy in children who receive traditional chemotherapy or experimental therapies prior to transplantation. To address these limitations, Archambeault and Loh have developed a novel method of detecting minimal residual disease to 
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follow response to therapy by merging TaqMan chemistry with a mismatched amplification mutation assay (MAMA), referred to as TaqMAMA [50] . This method is based on the preferential amplification of the mutant allele compared to the wild type allele. These assays were developed to follow the most common PTPN11 (226G > A, 214G > A, 227A > G, and 1508G > C), KRAS (38G > A and 35G > A), and NRAS (38G > A and 37G > C) mutations found in JMML, were ade quately sensitive to detect the mutant alleles, and were very specific for seven of the eight mutant alleles examined. Impor tantly, detection of the mutant allele from peripheral blood cells correlated very well with detection from bone marrow cells, suggesting that tracking disease burden by peripheral blood draws rather than by multiple bone marrow aspirations is feasible using this method. Furthermore, the TaqMAMA method detected disease relapse either earlier or simultaneous to disease relapse detection determined by the conventional autologous cell chimerism method. Collectively, these find ings suggest that the TaqMAMA methodology provides a potentially powerful tool for following response to upfront novel therapies and for detecting minimal residual disease following transplantation in children with JMML.
Current therapy
Unfortunately, JMML has proved to be resistant to essen tially all chemotherapy regimens examined including single agents as well as combination chemotherapy typically uti lized in acute leukemias [6] . The only curative therapy is allogeneic stem cell transplantation which is able to cure approximately 50% of patients; however, the leading cause of death following transplantation continues to be leukemia relapse [7, 51, 52] . Some patients who suffer from relapse are cured from a secondary allogeneic transplant [53] . Two main retrospective studies have been published evaluating the efficacy of allogeneic transplantation in JMML. First, the Japanese Society of Pediatric Hematology (JSPH) published a series of 27 patients diagnosed with JMML based on cri teria outlined by the International JMML Working Group. Although the preparative regimens and graft sources varied widely, this retrospective evaluation demonstrated an over all survival of 57.9% and an event free survival of 54.2% at 4 years after allogeneic transplantation [54] . A second trial with 100 children conducted by the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EMBT) Group used a prepar ative regimen consisting of busulfan (16-20 mg/kg over 4 consecutive days), cyclophosphamide (60 mg/kg/d for 2 con secutive days), and melphalan (140 mg/m 2 , single dose). Graft sources varied from bone marrow, peripheral blood, or cord blood. Similar to the JSPH study, children undergo ing allogeneic transplantation achieved an overall survival of 64% and event free survival of 52% [7] . Other anal yses from this study revealed no significant difference in event free survival between children receiving grafts from siblings v. unrelated donors or between splenectomized v. non-splenectomized patients at the time of transplant. Event free survival was significantly increased in males and in children < 2 years of age at the time of JMML diagnosis, con sistent with the finding of increased survival in children <1 year at the time of diagnosis demonstrated in the JSPH study. However, findings from the EWOG/EBML trial revealed no difference in event free survival between patients with normal vs. karyotypic abnormalities while the JSPH trial demon strated a significant reduction in overall survival in patients with karyotypic abnormalities [7, 54] . Two subsequent studies have been performed by the JPHS. Patients on trial MDS 99 received busulfan (140 mg/m 2 × 4 doses), cyclophosphamide (60 mg/kg × 2 doses), and high dose cytarabine (3 gm/m 2 × 4 doses). In this study, the investigators observed a 50% dis ease free survival. Upon subgroup analysis, disease free survival was better in individuals with a normal karyotype as well as patients experiencing either acute or chronic graft vs. host disease. In a second trial, a conditioning regi men including busulfan (140 mg/m 2 × 4 doses), fludarabine (30 mg/m 2 × 4 doses), and LPAM (90 mg/m 2 × 2 doses) pro duced a disease free survival of 75% at 6 years following transplant. In short, although a rigorous intervention, allo geneic stem cell transplantation provides a real chance of cure for children suffering from JMML. However, scientists and clinicians continue to study JMML aggressively in basic research labs in a concerted effort to define novel therapeu tic targets and to develop effective, less toxic, therapeutic interventions.
Experimental therapies
Although allogeneic transplant does provide a curative modality for JMML, there are significant morbidities associ ated with this aggressive intervention; thus, improved and less toxic therapies are currently under evaluation. Given the importance of Ras hyperactivation in the pathophysi ology of JMML, agents designed to target Ras activity are being evaluated. Ras is first activated at the cell membrane via the addition of a farnesyl group to the newly trans lated protein. Farnesyl transferase inhibitors (FTIs) prevent Ras translocation to the plasma membrane by inhibiting Ras isoprenylation, thus leading to downregulation of Rasactivated cellular pathways [55] . It was thus hypothesized that inhibiting farnesyl transferase activity may inhibit Ras activation, despite the knowledge that an alternative path way to Ras activation occurs by geranylgeranylation. In vitro studies demonstrated significant growth inhibition of JMML patient samples by the peptidomimetic FTIs, L 739,749 and L-744,832 [56] . Based on these in vitro findings, Castleberry, Emanuel, and co-workers recently completed a phase II window clinical trial (AML0122) designed to evaluate the dosing and potential effectiveness of R115777, a non-peptidomimetic FTI, in newly diagnosed, previously untreated JMML patients.
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Patients received two courses of R115777 (200 mg/m 2 or 300 mg/m 2 by mouth each day for 21 days) followed by two courses of cis-retinoic acid, cytarabine, and fludara bine, splenectomy, and allogeneic transplantation. Following administration of R115777, response to therapy was assessed by white blood cell counts and organomegaly based on cur rent guidelines for JMML response criteria (Table 3a) . A total of 11 patients received 200 mg/m 2 for two courses. The therapy was well tolerated and six patients achieved a par tial response, one patient achieved a marginal response, two maintained stable disease, and one demonstrated progressive disease. A total of 36 patients received 300 mg/m 2 for two courses. Among this group, two patients achieved a complete remission, 14 achieved a partial response, seven a marginal response, two maintained stable disease, and three demon strated progressive disease. Taken together, 81% of patients demonstrated a clinical response to R115777 (including all with complete, partial, and marginal responses at both doses administered). The main toxicity induced by R115777 was bone marrow suppression. Response or lack of response to the drug was not correlated with patient mutational status (NF1, KRAS, NRAS, PTPN11, or monosomy 7), nor was inhibition of farnesyl transferase activity as measured by the surrogate prenylation of the heat shock molecule, HDJ2 [57] . Unfortunately, preliminary findings presented at the 2nd International JMML Symposium indicated that event-free survival did not appear to be favorably impacted by the use of R115777 compared to the outcomes of other trials; however, this trial is ongoing and the data has not matured. Thus, the event-free survival and overall survival of patients receiving R115777 prior to allogeneic transplantation continues to be evaluated.
In addition to directly targeting Ras, agents that target Ras effectors within the MAPK cascade, such as RAF-1 and MEK, are also being evaluated in myeloid leukemias. Previ ous in vitro and in vivo studies demonstrated that treatment of JMML cells with a DNA enzyme designed to target RAF1 mRNA, thus reducing RAF1 expression, resulted in reduced hypersensitivity of JMML cells to GM-CSF and reduced mor tality of NOD-SCID mice transplanted with JMML cells, respectively [58] . Based on these findings, a phase II win dow clinical trial is under development to evaluate response rate and acute toxicity of JMML patients to sorafenib (BAY 43-9006), a RAF kinase inhibitor.
Additionally, Lauchle and colleagues have evaluated the effect of CI-1040, a selective MEK inhibitor, on Nf1 −/− MPD [41] and Nf1 −/− AML (induced by infection of Mx1-Cre, Nf1 flox/flox mice [41] with a retroviral insertional mutagen, MOL4070LTR) [59] . While Nf1 mutant MPD cells were not more sensitive to CI-1040 inhibition compared to WT cells, the Nf1 mutant AML cells demonstrated significant sensitivity to CI-1040 inhibition. Similarly, in vivo admin istration of CI-1040 to Nf1 mutant mice with MPD did not improve survival; however, CI-1040 treatment of mice transplanted with Nf1 mutant AML cells demonstrated signif icantly increased survival compared to vehicle-treated mice.
Interestingly, AML clones that demonstrated resistance to CI-1040 were found to have novel retroviral integration sites, suggesting that cooperating mutations can modulate response to CI-1040 [59] .
Conclusions
Tremendous clinical and scientific advances have been made in JMML over the last 20 years; however, regrettably, up to 50% of JMML patients continue to succumb to this lethal malignancy. The goals continue to be improved understand ing of the disease at a molecular level in an effort to identify rational therapeutic targets and efficient and successful trans lation of our mechanistic understanding into superior, less toxic therapeutic modalities for JMML. Furthermore, ideally, JMML will serve as a model disease leading to improved ther apies for leukemias and solid tumors, in general, bearing Ras hyperactivation as a central pathogenic mechanism.
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